- Roche launches COVID-19 PCR test to detect the fast spreading XBB.1.5 Omicron sub-variant
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
- Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
- FDA grants priority review to Roche’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma
- FDA approves Roche’s Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphoma
- FDA approves Roche’s Actemra for the treatment of COVID-19 in hospitalised adults
- CHMP recommends expansion of EU label for Hemlibra to include people with moderate haemophilia A
- Roche announces U.S. collaboration with Pfizer to help patients who test positive for COVID-19 navigate risks, symptoms, testing and treatment options
- Roche presents new data demonstrating the potential benefit of glofitamab and Lunsumio as fixed-duration, off-the-shelf treatment options for lymphoma
- Roche presents new and updated data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022
More ▼
Key statistics
SmartText not available for this item.
52-week range
Markit short selling activity
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 247.00 |
Average volume | -- |
---|---|
Shares outstanding | 809.25m |
Free float | 728.90m |
P/E (TTM) | 16.35 |
Market cap | 239.64bn CHF |
EPS (TTM) | 17.67 CHF |
Annual div (ADY) | 8.95 EUR |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Mar 17 2022 |
Div pay-date | Mar 21 2022 |
Data delayed at least 15 minutes, as of Jun 28 2019 17:47 BST.
More ▼